TSHA:NASDAQ, Taysha Gene Therapies, Inc.

TSHA stock overview

Taysha Gene Therapies, Inc. (TSHA:NASDAQ) closed at $3.72 on November 20, 2026, down 1.33% on the day. The stock trades 49.0% below its 52-week high of $7.30 and 7.7% above its 52-week low of $3.46. Over the past year, it lost 11.2%. Taysha Gene Therapies, Inc. is part of the Health Care sector.

Key figures

Price
$3.72
Day change
-1.33%
Volume
3,149,828
Average volume
3,586,920
Market cap
1B+
52-week range
$3.46 – $7.30
50-day average
$4.38
200-day average
$5.29

Price action over the past year

In 252 trading sessions since November 20, 2025, TSHA closed higher on 117 days (46%). Its best day was April 15, 2026 (+27.39%) and its worst was July 13, 2026 (-15.14%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

TSHA news

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Similar stocks

Find more stocks like TSHA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.